Jones RH, Casbard A, Carucci M, Cox C, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an
aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer
(FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020 Feb 5. pii: S1470-2045(19)30817.
PMID: 32035020